BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 23, 2006
 |  BioCentury  |  Strategy

Protein space race continues

Two recent deals by Ablynx N.V. illustrate the ongoing rush by big pharma companies to make sure they are players in the next-generation antibody/protein space.

In the past two weeks, Ablynx has signed deals covering therapeutic applications of its Nanobody platform with Novartis AG (NVS; SWX:NOVN, Basel, Switzerland) and Centocor Research & Development Inc. (Malvern, Penn.), a subsidiary of Johnson & Johnson (JNJ, New Brunswick, N.J.) (see B2 & BioCentury, Jan. 16).Nanobodies are single-domain antibody fragments derived from camelid antibodies that lack a light chain - a property that confers potentially significant advantages over both conventional antibodies and their fragments. These include high stability under conditions of high heat, high pH and the presence of enzymes; the potential for...

Read the full 586 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >